Philip Martin

机构：AstraZeneca (Singapore) · ORCID：0000-0002-8456-9725

发表论文 770 篇 · 总被引 12762 次 · h-index 55

代表论文

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors (2023 · Cancer Immunology Immunotherapy · 被引 125)
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer (2023 · Journal of Clinical Investigation · 被引 58)
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation (2023 · Journal of Clinical Investigation · 被引 55)
California has 882,000 farmworkers to fill 413,000 jobs (2024 · California Agriculture · 被引 17)
Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue (2023 · Clinical Proteomics · 被引 9)
Exploring the Expression of Adenosine Pathway-Related Markers CD73 and CD39 in Colorectal and Pancreatic Carcinomas Characterized by Multiplex Immunofluorescence: A Pilot Study (2023 · Pathobiology · 被引 7)